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introduction: The effects of bacterial infections on the response to subsequent viral 
infections are largely unknown. This is important to elucidate to increase insight into the 
pathophysiology of bacterial and viral co-infections, and to assess whether bacterial 
infections may influence the course of viral infections.
Methods: Healthy male subjects received either bacterial endotoxin [Escherichia 
coli-derived lipopolysaccharide (LPS), 2 ng/kg, n = 15] or placebo (n = 15) intravenously, 
followed by intranasal Fluenz (live-attenuated influenza vaccine) 1 week later.
results: LPS administration resulted in increased plasma cytokine levels and devel-
opment of endotoxin tolerance in  vivo and ex vivo, illustrated by attenuated cytokine 
production upon rechallenge with LPS. Following Fluenz administration, infectivity for 
the Fluenz A/B strains was similar between the LPS–Fluenz and placebo–Fluenz groups 
(13/15 subjects in both groups). Also, the Fluenz-induced increase in temperature and 
IL-6, G-CSF and IP-10 concentrations in nasal wash were similar between both groups.
conclusion: While endotoxemia profoundly attenuates the immune response upon 
a second LPS challenge, it does not influence the Fluenz-induced immune response. 
These results suggest immune suppression after bacterial infection does not alter the 
response to a subsequent viral infection.
Keywords: sepsis, lipopolysaccharide, endotoxin tolerance, influenza, live-attenuated quadrivalent influenza 
vaccine, Fluenz, two-hit model
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inTrODUcTiOn
Secondary infections with a pathogen other than that which 
caused the primary infection are generally associated with an 
unfavorable prognosis compared with de novo infections (1). 
It may be rational to hypothesize that this is the consequence of 
immunological interplay between pathogen-specific pathways. 
Concerning the innate immune response, two phenomena have 
been described for these interactions. First, the primary challenge 
can induce immunosuppression or “tolerance.” This phenotype is 
increasingly recognized as the overriding immune dysfunction 
in bacterial sepsis, where it is known as sepsis-induced immu-
noparalysis, rendering patients unable to clear their primary 
infection and rendering them more susceptible toward second-
ary infections (2). We have previously demonstrated that human 
endotoxemia [intravenous challenge with bacterial lipopolysac-
charide (LPS) in healthy volunteers] results in the development of 
endotoxin tolerance, exemplified by a severely blunted immune 
response upon a second LPS challenge (3, 4). Second, the primary 
challenge can induce “priming” (5) or “training” (6), resulting in 
a more pronounced response following the secondary infection. 
As an example for that, bacille Calmette–Guerin vaccination 
results in enhanced immunological responses by cells of the 
innate immune system upon a subsequent challenge with a dif-
ferent pathogen (7).
Viral–bacterial interactions are well characterized in animal 
models, mainly using influenza infection followed by a challenge 
with live bacteria or LPS. These studies have demonstrated an 
initial influenza-induced hyperinflammatory state (priming) 
(8, 9), followed by an immunosuppressive state, which predis-
poses to secondary bacterial infections (10–12). By contrast, 
bacterial–viral immunological interactions are much less well 
studied, and no human data exist to date. The few in vitro studies 
that investigated this interplay have employed co-infection mod-
els, in which pretreatment with LPS takes place ≤24  h before 
influenza infection (13–15). In these studies, LPS pretreatment 
was shown to induce a primed response upon influenza chal-
lenge, characterized by the initiation of an enhanced type I 
immune response and decreased viral transcription (13–15). 
Furthermore, it was shown recently that commensal bacteria 
producing LPS significantly reduce the thermal stability of IAV 
in vitro, that LPS decreases stability of human and avian viral 
strains at physiological temperatures, and that LPS binds to and 
affects the morphology of influenza virions (16). In accordance 
with these in vitro data, intramuscular LPS injection in chicken 
followed by an intranasal influenza challenge 24 h later resulted 
in reduced influenza viral shedding 4 and 7 days later, compared 
with animals that did not receive LPS pretreatment. This was 
accompanied by pulmonary upregulation of interferon (IFN)-α 
and IFN-γ genes (17). IFNs are known for their antiviral func-
tions, such as inhibition of viral replication and activation of 
immune cells. However, their upregulation has also been associ-
ated with immunosuppression and the increased incidence of 
secondary infections (18).
In this study, we investigated the bacterial–viral interplay in 
humans in vivo in a unique two-hit model: human endotoxemia 
followed by a challenge with the mucosal live-attenuated influenza 
vaccine Fluenz. We used this approach as a model to assess the 
effects of a bacterial-induced immune response and development 
of endotoxin tolerance on the response to a subsequent infection 
with influenza, which is administered in another body compart-
ment: the respiratory mucosa.
MaTerials anD MeThODs
subjects
This randomized placebo-controlled study was registered at 
ClinicalTrials.gov (NCT02642237). After approval by the local 
medical ethics committee (CMO 2015/2058), 30 healthy, non-
smoking male subjects aged 18–35 years gave written informed 
consent to participate in the study. All study procedures were in 
accordance with the declaration of Helsinki, including the latest 
revisions. Subjects were screened before the start of the study and 
had a normal physical examination, electrocardiography, and 
routine laboratory values. Subjects were excluded if they had a 
preexistent (lung) disease, a suspicion of influenza infection in 
the preceding year or a (febrile) illness within 4  weeks before 
the LPS/placebo challenge. Subjects were not allowed to take 
(prescription) drugs and to have received a vaccination in the 
previous months. Subjects were asked to refrain from caffeine and 
alcohol intake 24 h, and from food 12 h before the LPS/placebo 
challenge.
To illustrate the development of in vivo endotoxin tolerance, 
we used cytokine data from our previously published double-
blind placebo-controlled randomized study (March–April 2012) 
in which the same inclusion criteria were used, healthy male 
subjects were administered endotoxin twice with an interval 
of 1 week [NCT01374711 (3)]. Only data from the six subjects 
that received placebo beside the endotoxin challenges were used. 
The human endotoxemia procedures employed in this study are 
identical to that of our previous study (3).
study Design
The study design is depicted in Figure 1. The study was performed 
from the 11th of January until the 26th of February 2016. Subjects 
were randomized by an independent nurse to receive an intrave-
nous bolus administration of LPS (2 ng/kg; n = 15) or placebo 
(0.9% saline; n = 15) on day 0. The procedures on day 0 were car-
ried out according to our standard human endotoxemia protocol 
(3). Seven days later (day 7), all 30 subjects underwent intranasal 
vaccination with the live-attenuated quadrivalent influenza vac-
cine (LAIV) Fluenz Tetra (0.1 ml/nostril). Subjects remained in 
the recumbent position for 1 min after Fluenz administration.
Lipopolysaccharide (US Standard Reference Endotoxin 
Escherichia coli O:113), obtained from the Pharmaceutical 
Development Section of the National Institutes of Health (Bethesda, 
MD, USA), supplied as a lyophilized powder, was reconstituted 
in 5 ml saline 0.9% for injection and vortex-mixed for 20 min 
after reconstitution. Fluenz Tetra (Medimmune LLC, Nijmegen, 
The Netherlands), complied with the WHO recommendation 
(Northern Hemisphere) and EU decision for the 2015/2016 season 
and contained the following strains: A/California/7/2009 (H1N1)
pdm09-like, A/Switzerland/9715293/2013 (H3N2)-like strain, 
FigUre 1 | Experimental design.
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B/Brisbane/60/2008 (Victoria lineage)-like strain, B/Phuket/ 
3073/2013 (Yamagata lineage)-like strain, all at 107.0±0.5 FFU*** 
per 0.2 ml dose.
Fluenz infectivity was defined as positive viral load (measured 
by real time PCR) in nasal washings for at least one of the influ-
enza strains from day 9 onward and/or seroconversion [defined 
as ≥4-fold increase in IgG-antibody titer for at least one of the 
four influenza strains present in the vaccine at 4 weeks postvac-
cination (day 35) compared with the day of vaccination (day 7)]. 
For viral load, we assessed Fluenz infectivity from day 9 onward, 
because Fluenz detected in nasal wash on the first day after vac-
cination (day 8) most likely originated from the vaccination and 
does not indicate actual viral replication.
nasal Wash
Nasal washings for viral RNA, flow cytometric determinations, 
leukocyte counts, and cytokine quantification were collected 
as described previously (19). Nasal wash from two nostrils 
was pooled and directly analyzed or centrifuged (2,000 g, 4°C, 
10 min), and stored at −80°C until further analysis.
Viral load
Viral load was semi-quantitatively measured for the Influenza 
A (with subtype analysis for H1N1 and H3N2) and influenza B 
strains. Viral load was determined from nasal wash using the 
MagNA Pure 96 (MagNA Pure 96 DNA and Viral NA Small 
Volume Kit), and PCRs were performed on the LightCycler 
480 with Probes Master Mix (Roche Diagnostics, Almere, The 
Netherlands) using commercial validated primer and probe 
mixes (Tib-Molbiol GmbH, Berlin, Germany). Cycling condi-
tions were 95°C for 5 min, followed by 40 cycles of 95°C (15 s), 
55°C (15  s), and 72°C (20  s). The relative virus amount was 
determined based on the difference in cycle threshold value 
(Ct value) compared with baseline (day 7), at which virus was 
undetectable (Ct > 40, so Ct was set at 40) in all subjects included 
for analysis, and expressed as fold change using the formula 2DCt
, where ΔCt equals 40 − (Ct value on day x). The real time PCR 
for Fluenz was performed at the clinical laboratory of microbi-
ology at the Radboud University Medical Center. This labora-
tory is ISO certified and participates regularly with QCMD 
quality controls. The influenza strains measured included: 
influenza A, influenza B, and influenza A subtypes: influenza 
A/California/7/2009 (H1N1) and A/Switzerland/9715293/2013 
(H3N2). The PCR assay for influenza A and influenza B was 
more sensitive than the PCR for the influenza A subtypes 
(H1N1/H3N2), leading to lower Ct values for influenza A and 
influenza B. We only measured the influenza A and influenza 
B strains that were present in the vaccine and no wild-type 
influenza types, because detection of influenza A and B strains 
by PCR cannot differentiate between vaccine and wild-type 
influenza subtypes We excluded subjects in which Ct values of 
a particular influenza strain increased again after a period of 
absence of detectable influenza for this strain, or when the PCR 
was negative in the first 2 days after vaccination (days 8–9) but 
became positive in follow-up samples. The latter was the case in 
one subject (see Figure 2, subject with co-infection). Subjects 
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were also excluded when fever or clinical symptoms appeared 
for a second time or appeared very late after inoculation with 
Fluenz. This was also the case in the excluded subject mentioned 
earlier.
serology
Hemagglutination inhibition (HI) assays were performed for the 
detection of influenza virus specific antibodies. Serum samples 
were tested for the presence of antibodies to influenza viruses 
using the HI assay that was performed in duplicate according to 
standard methods (20, 21). All sera were treated with a filtrate 
of Vibrio cholerae as a source of receptor destroying enzyme and 
heat inactivated at 56°C. Twofold serial dilutions of the serum 
samples, starting at 1:20, were incubated with four hemagglu-
tinating units of virus propagated in 11-day-old embryonated 
chicken eggs for 30 min at 37°C. Subsequently turkey erythro-
cytes were added, incubated for 1 h at 4°C, and hemagglutina-
tion patterns were recorded. For this purpose, vaccine strains 
NIB-88 [A/Switzerland/9715293/13-like (H3N2)], X-181 [A/
California/7/09-like (H1N1)pdm09], B/Phuket/3073/13, or B/
Brisbane/060/08 were used. Ferret sera raised against the test 
antigens were used as positive controls. The paired serum samples 
of each individual study subject were tested simultaneously. For 
statistical analysis, a titer of 5 was arbitrarily assigned to sera with 
a titer <10. Titers were transformed to a logarithmic scale, and 
geometric means were used for further calculations.
hemodynamic Parameters, symptoms, 
and Temperature
On day 0, heart rate (3-lead electrocardiogram) and intra-
arterial blood pressure data were recorded from a Philips MP50 
patient monitor (Philips, Eindhoven, The Netherlands) every 
30  s by a custom in-house developed data recording system. 
On the same day, the LPS-induced rise in temperature and 
flu-like symptoms (headache, nausea, shivering, muscle pain, 
and back pain) were scored every 30  min on a 6-point scale 
(0 =  no symptoms, 5 =  worst ever experienced), resulting in 
a total score of 0–25. To assess Fluenz-induced local, lower 
respiratory tract and systemic symptoms, all subjects filled 
out an online symptom diary (LimeSurvey Project Hamburg, 
Germany), using the validated Jackson score [summing the 
following symptoms: sneezing, nasal discharge, nasal obstruc-
tion, sore throat, cough, headache, malaise, and chilliness (22)]. 
Symptoms were assessed before Fluenz vaccination and then 
daily until day 28. The severity of each symptom was rated on a 
4-point scale. Body temperature was measured using an infra-
red tympanic thermometer (FirstTemp Genius 2, Sherwood 
Medical, Crawley/Sussex, UK).
Peak expiratory Flow (PeF)
Peak expiratory flow was measured using a peak flow meter PFM20 
(Omron Healthcare Europe B.V., Hoofddorp, The Netherlands). 
PEF was determined twice during each visit and the highest value 
was used. An affected lower respiratory tract was defined as >20% 
decrease in PEF compared with the predicted values of subjects’ 
corresponding age, gender, and stature (23).
leukocyte counts
Analysis of leukocyte counts and differentiation from EDTA anti-
coagulated blood and nasal wash were measured using routine 
analysis methods also used for patient samples (flow cytometric 
analysis on a Sysmex XE-5000).
Ex Vivo Monocyte stimulation
Primary monocytes were isolated and stimulated as described 
previously (24). The mononuclear cell fraction was isolated by 
density centrifugation of EDTA anticoagulated blood, diluted 1:1 
in pyrogen-free saline over Ficoll-Paque (GE Healthcare, UK). 
Isolated cells were washed twice in PBS, and monocyte isolation 
was subsequently performed using CD14 positive magnetic beads 
(MACS Miltenyi). MACS isolation was performed according to 
the manufacturer’s protocol. Monocytes were resuspended in 
culture medium (RPMI, Invitrogen, Carlsbad, CA, USA) supple-
mented with 10 µg/ml gentamicin, 10 mM glutamax, and 10 mM 
pyruvate. Cell counts were performed using a Coulter counter 
(Coulter Electronics). 1 × 105 monocytes in a 100 µl volume were 
plated in 96-well flat-bottom plates (Corning, NY, USA) and 
stimulated for 24 h at 37°C in 5% CO2 with 100 µl of RPMI, LPS 
(10 ng/ml, serotype 055:B5, Sigma-Aldrich), heat-killed Candida 
albicans (1 × 106/ml, strain UC820), and Staphylococcus aureus 
(1 × 106/ml, clinical isolate). Supernatants were stored at −20°C 
until cytokine analysis.
cytokine analysis
For plasma cytokine concentrations, EDTA anticoagulated blood 
was centrifuged (2,000 g, 4°C, 10 min) and stored at −80°C until 
analysis. Concentrations of cytokines in plasma, nasal wash, and 
supernatants of stimulated monocyte cultures were determined 
by simultaneous Luminex assay (R&D Systems; Abingdon 
Science Park, UK) and enzyme-linked immunosorbent assays 
(ELISAs) (R&D Systems, Minneapolis, MN, USA). TNF-α, IL-6, 
and IL-10 were measured in plasma samples collected on day 0 
using a simultaneous Luminex assay (R&D Systems; Abingdon 
Science Park, UK). In samples obtained from day 7 onward, 
G-CSF, IL-6, IL-8, IL-10, and IFN-γ in nasal wash were measured 
using a Luminex assay from R&D Systems (Minneapolis, MN, 
USA), and IFN-α and IFN-β were measured by a Luminex assay 
from eBioscience (Vienna, Austria). IP-10 concentrations in nasal 
wash and plasma were measured using an ELISA (R&D Systems, 
Minneapolis, MN, USA). Lower detection limits in plasma were 
1.2 pg/ml for TNF-α, IL-6, and IL-10, and 156 pg/ml for IP-10. 
In nasal wash, lower detection limits were 309 pg/ml for IP-10, 
0.49 for IFN-α and IFN-β, and 1.4 pg/ml for the remaining ana-
lytes. Cytokines in supernatants of ex vivo stimulated monocytes 
were measured using ELISA (IL-1β and IL-13: R&D Systems, 
Minneapolis, MN, USA, IL-6 and IL-10: Sanquin, Amsterdam, 
The Netherlands) following the protocols of the manufacturers.
statistical analysis
Data are presented as mean ± SEM, median [IQR] or geometric 
mean (95% CI). Between-group comparisons were made using 
Mann–Whitney U tests, Kruskal–Wallis tests, Wilcoxon matched-
pairs tests, or repeated measures two-way ANOVAs (interaction 
Table 1 | Demographic characteristics of the 30 subjects who participated in the study, including the 6 subjects from our previous study, in which subjects received 
lipopolysaccharide (LPS) twice.
lPs–lPs (n = 6) Placebo–Fluenz (n = 15) lPs–Fluenz (n = 15) Total group (n = 30) p-Value between groups
Age (years) 21 [20–23] 21 [20–23] 22 [19–23] 21 [20–23] 0.83
Height (cm) 183 [176–189] 180 [178–188] 186 [178–190] 182 [178–189] 0.36
Weight (kg) 81 [75–89] 75 [70–84] 79 [71–87] 78 [69–85] 0.52
BMI (kg/m2) 24 [23–26] 23 [20–26] 23 [22–25] 23 [21–25] 0.64
Parameters were measured during the screening visit.
BMI, body mass index.
Data are presented as median [IQR].
FigUre 2 | Flowchart based on infectivity, defined as positive viral load for at least one of the influenza strains >day 7 and/or seroconversion (≥4-fold increase in 
antibody titer for at least one of the influenza strains at day 28 postvaccination compared with baseline). One subject in the placebo–Fluenz group became positive 
again for one of the influenza strains and was therefore considered to have a co-infection with influenza virus. This subject was excluded for further analyses.
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term) as appropriate, the latter after log transformation if data 
were not normally distributed (based on the Shapiro–Wilk 
test). Categorical data were analyzed using Fisher exact tests. 
Spearman correlation was used. For reasons of clarity, in case of 
multiple lines in one graph and a logarithmic y-axis, only upper 
or lower bounds of the 95% CI are shown. Statistical analyses 
were performed using GraphPad Prism version 5.0 (GraphPad 
Software, San Diego, CA, USA). p-Values < 0.05 were considered 
statistically significant.
resUlTs
Demographic characteristics
Demographic characteristics of the study population are listed 
in Table 1. We also included the six subjects from our previous 
study, in which subjects received LPS twice. There were no differ-
ences in baseline characteristics between the groups.
LPS/Placebo Challenge
LPS-Induced Immune Response In Vivo
As expected, plasma levels of TNF-α, IL-6, and IL-10 increased 
profoundly in the LPS group, but not in the placebo group 
(Figure 3). This cytokine response was accompanied by a tran-
sient monocytopenia, lymphocytopenia, and neutrophilia in the 
LPS group (Figure 4). In both groups, blood pressure decreased 
during the experimental day, and this was more pronounced 
in the LPS than in the placebo group (Figure 5). Only subjects 
in the LPS group showed an increase in heart rate (Figure  5). 
LPS-induced symptoms typically started 1  h following LPS 
administration and peaked at 90 min after LPS administration, 
accompanied by an increase in body temperature to 38.2 ± 0.1°C 
(Figure 5).
To illustrate the blunted in vivo immune response toward a 
second LPS challenge 1 week after the first LPS administration, 
we used data from a previous study in which subjects received 
LPS twice (with an interval of 1  week) using the exact same 
endotoxemia protocol as used in this study (3). Upon the second 
LPS administration, peak plasma levels of the cytokines such as 
TNF-α, IL-6, and IL-1RA were reduced by a median [IQR] of 74% 
[61–83], 79% [66–88], and 53% [47–88], respectively, illustrative 
of profound in vivo endotoxin tolerance (Figure 6).
Ex Vivo Cytokine Responses
Ex vivo stimulation of monocytes with LPS, C. albicans, or 
S. aureus demonstrates clear immunosuppression at 4 h after LPS 
FigUre 5 | Hemodynamic and clinical parameters in 30 subjects who received an intravenous administration of lipopolysaccharide (LPS) (n = 15) or placebo 
(n = 15) at T = 0. Data are represented as mean ± SEM.
FigUre 4 | Circulating leukocyte numbers in 30 subjects who received an intravenous administration of lipopolysaccharide (LPS) (n = 15) or placebo (n = 15) at 
T = 0. Data are represented as mean ± SEM.
FigUre 3 | Plasma levels of the cytokines TNF-α, IL-6, and IL-10 in 30 
subjects who received an intravenous administration of lipopolysaccharide 
(LPS) (n = 15) or placebo (n = 15) at T = 0. Data are represented as median 
[IQR].
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administration, illustrated by significant attenuation of IL-1β 
and IL-6 production following endotoxemia, compared with the 
placebo group (Figure 7).
Fluenz Challenge
Viral Load and Antibody Responses
A flowchart of the study based on Fluenz infectivity is depicted 
in Figure 2. In 26 of the 30 subjects (87%), Fluenz inoculation 
resulted in infectivity, with identical rates in the LPS–Fluenz 
and LPS-placebo groups (13 out of 15 subjects in both groups). 
Three subjects showed no increase in viral load after Fluenz 
inoculation and one subject in the placebo–Fluenz group showed 
a second increase in viral load, suggestive for co-infection with 
a wild-type influenza strain. These subjects were excluded from 
further analysis (see Figure 2). Changes in viral load are depicted 
in Figure  8. Influenza A viral load peaked 1  day after Fluenz 
FigUre 6 | Peak plasma levels of IL-1RA, IL-6, and TNF-α in six subjects who were challenged with lipopolysaccharide (LPS) twice, separated by 1 week. Data are 
represented as Box and Whisker (Min to Max) plots of individual peak levels of plasma cytokine concentrations during the first and second lipopolysaccharide (LPS) 
challenge. Data previously published (3).
FigUre 7 | Production of IL-6 and IL-1β measured in supernatants of ex vivo stimulated monocytes of 30 subjects who received lipopolysaccharide (LPS) (n = 15) 
or placebo (n = 15) at T = 0. Monocytes were stimulated with LPS, Candida albicans, and Staphylococcus aureus. Cytokine production was measured at T = 0 
(baseline) and 4 h after administration of LPS/placebo. Data are represented as mean ± SEM.
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vaccination to 26 (20–83) and 16 (10–27) fold change in the 
LPS–Fluenz and placebo–Fluenz group, respectively (p = 0.54). 
Viral load of the influenza B strain peaked to 14 (11–40) and 
29 (20–64) fold change in the LPS–Fluenz and placebo–Fluenz 
group, respectively (p = 0.45). Subtyping of the influenza A strain 
showed only a slight and short-lived increase for the H1N1 strain 
and a more substantial and sustained increase for the H3N2 
strain, with no differences between groups (Figure 8). Viral load 
gradually returned to baseline levels in the following weeks, with 
no differences between the LPS and placebo pretreatment groups. 
Antibody responses over time against the four strains present in 
the vaccine were also mainly driven by the H3N2 response and 
comparable between groups (Figure 9). Likewise, the proportion 
of subjects that displayed seroconversion was similar between 
groups [10 out of 13 (77%) in the LPS–Fluenz group and all 13 
subjects in the placebo–Fluenz group, p =  0.22]. Detailed data 
concerning the antibody responses per strain are listed in Table 2.
Cytokines and Leukocytes in Nasal Wash
In both study groups, nasal wash levels of the cytokines IL-6 and 
G-CSF, and the chemokine IP-10 increased after Fluenz vaccina-
tion to a similar extent (Figure 10). The cytokines/chemokines 
IL-8, IL-10, IFN-α, IFN-β, and IFN-γ were below detection limits 
in virtually all subjects at all time points, and no clear differences 
between placebo and LPS groups were observed following Fluenz 
vaccination. Neither total leukocyte counts nor numbers of 
FigUre 8 | Viral load of the influenza A and B strains as well as the influenza A subtypes H1N1 and H3N2 in nasal wash of the 26 subjects who were challenged 
with lipopolysaccharide (LPS) (n = 13) or placebo (n = 13) on day 0 and displayed infectivity after inoculation with Fluenz on day 7. Data are presented as geometric 
means with 95% CI of fold changes in viral load compared with baseline, where viral load was undetectable (Ct > 40, so Ct was set at 40). The italic numbers placed 
under the time points indicate how many subjects were PCR positive for the respective strain in each group.
FigUre 9 | IgG titers for the different influenza strains in 26 subjects who were challenged with lipopolysaccharide (LPS) (n = 13) or placebo (n = 13)  
on day 0 and displayed infectivity after inoculation with Fluenz on day 7. Data are represented as geometric mean with 95% CI.
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mononuclear cells and neutrophils in nasal wash were affected 
by Fluenz vaccination, and no differences between groups were 
observed (Figure 11).
Local and Systemic Symptoms, Temperature, and PEF
Symptoms indicative for local inflammation of the nasal mucosa 
in the upper respiratory tract (such as sneezing, nasal discharge, 
Table 2 | Results of the hemagglutination inhibition (HI) assay for the various 
influenza strains present in the vaccine in the 26 subjects who were challenged 
with lipopolysaccharide (LPS) (n = 13) or placebo (n = 13) on day 0 and were 
inoculated with Fluenz on day 7.
Placebo–
Fluenz
lPs– 
Fluenz
Total % seroconversion 13/15 (87%) 10/15 (77%)
a (h1n1)
Baseline HI titer > 1:20 (seropositives) 12/15 (80%) 14/15 (93%)
Seroconversion (day 35) 4/15 (27%) 1/15 (7%)
a (h3n2)
Baseline HI titer > 1:20 (seropositives) 6/15 (40%) 7/15 (47%)
Seroconversion (day 35) 11/15 (73%) 10/15 (67%)
b (Phuket)
Baseline HI titer > 1:20 (seropositives) 6/15 (40%) 7/15 (47%)
Seroconversion (day 35) 0/0 (0%) 0/0 (0%)
b (brisbane)
Baseline HI titer > 1:20 (seropositives) 6/15 (40%) 5/15 (33%)
Seroconversion (day 35) 2/15 (13%) 0/0 (0%)
GMT H1N1 at baseline 69 (26–184) 82 (43–158)
GMT H1N1 at day 35 158 (83–303) 66 (40–108)
GMT H3N2 at baseline 14 (6–33) 10 (5–21)
GMT H3N2 at day 35 128 (60–275) 115 (46–286)
GMT B (Phuket) at baseline 11 (5–24) 12 (6–24)
GMT B (Phuket) at day 35 10 (5–17) 10 (6–18)
GMT B (Brisbane) at baseline 11 (6–20) 10 (5–22)
GMT B (Brisbane) at day 35 12 (5–26) 9 (5–16)
GMT, geometric mean titer with 95% CI.
FigUre 10 | Cytokines in nasal wash in the 26 subjects who were challenged with lipopolysaccharide (LPS) (n = 13) or placebo (n = 13) on day 0 and displayed 
infectivity after inoculation with Fluenz on day 7. Data are represented as geometric mean with 95% CI.
FigUre 11 | Total leukocyte counts, numbers of mononuclear cells, and neutrophils in nasal wash in the 26 subjects who were challenged with  
lipopolysaccharide (LPS) (n = 13) or placebo (n = 13) on day 0 and displayed infectivity after inoculation with Fluenz on day 7. Data are represented as  
geometric mean with 95% CI.
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nasal obstruction, sore throat, and cough) did not show a clear 
increase after Fluenz vaccination and were similar in both 
groups (maximum levels of 2 [0–5.5] vs. 3 [2–5.5] symptom 
points in the LPS–Fluenz and placebo–Fluenz groups, respec-
tively, p = 0.42). Systemic symptoms (headache, malaise, and 
chilliness) were not encountered in any of the subjects. Body 
temperature increased to peak levels of 37.0 [36.9–37.2]°C and 
37.2 [36.9–37.3]°C in the LPS–Fluenz and placebo–Fluenz 
groups, respectively, p  =  0.52 (Figure  12). Finally, Fluenz 
vaccination did not affect PEF, as all subjects produced values 
>80% of their individual predicted values at all time points 
(Figure 12).
Plasma IP-10 Levels and Circulating Leukocytes
Plasma levels of the chemokine IP-10 did not increase following 
Fluenz vaccination and no differences in circulating leukocyte 
counts or differentiation were observed (data not shown).
DiscUssiOn
This study demonstrates that a challenge with LPS and the result-
ing development of profound tolerance to a subsequent challenge 
with the same agent does not influence the immune response 
induced by a subsequent viral challenge with the mucosal LAIV 
Fluenz.
FigUre 12 | Temperature and peak expiratory flow (PEF) in the 26 subjects who were challenged with lipopolysaccharide (LPS) (n = 13) or placebo (n = 13) on day 
0 and displayed infectivity after inoculation with Fluenz on day 7. Data are represented as geometric mean with 95% CI.
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In bacterial sepsis, a tolerant state called “sepsis-induced 
immunoparalysis” renders the host unable to clear the primary 
infection and increases the susceptibility toward secondary 
infections (1). These secondary infections include bacterial 
and fungal infections, while reactivation of viruses that reside 
latently in the human host is also frequently encountered (25). 
However, it was unknown to what extent the development of 
an endotoxin-tolerant phenotype following bacterial infection 
influences the innate host response toward a viral challenge. 
Herein, we employed a unique two-hit model in humans in vivo, 
consisting of a challenge with LPS followed by a Fluenz challenge. 
This study, as well as previous studies (3, 4, 26–28), show that LPS 
administration results in the development of endotoxin tolerance 
in vivo and ex vivo, illustrated by a profound attenuation of the 
cytokine response upon a subsequent LPS challenge. As such, 
human endotoxemia can serve as a model for bacterial sepsis 
and the associated development of immunoparalysis, and has 
already been used to investigate potential therapies to reverse 
sepsis-induced immunoparalysis (3).
The live-attenuated, quadrivalent influenza vaccine “Fluenz 
Tetra” contains four different influenza strains recommended 
by international public health agencies as most likely to provide 
protection against seasonal influenza in any given year (29). 
Fluenz is a vaccine applied to the nasal mucosa; the natural 
entrance of respiratory viruses. Therefore, Fluenz vaccination 
can be used to model influenza infection in humans in  vivo, 
albeit a very mild infection, as the response to LAIVs is 
much less pronounced than to live pathogenic influenza (30). 
Nevertheless, we believe that LAIVs such as Fluenz are the clos-
est to live pathogenic influenza virus that can be safely used in 
healthy volunteers.
Our data show that a preceding LPS challenge neither influ-
enced infectivity and innate immune parameters (illustrated 
by identical cytokine responses in nasal wash) nor impacted 
measures of adaptive immunity (such as antibody levels and 
rate of seroconversion), following Fluenz vaccination. These 
results do not correspond with previous in  vitro and in  vivo 
findings, where immunological priming was observed (13–15, 
17). Furthermore, our findings are different than those from 
to earlier ex vivo work, where it was shown that leukocytes 
from healthy volunteers undergoing human endotoxemia 
demonstrated a profound tolerant phenotype upon ex vivo 
stimulation with the viral ligands poly(I:C) and S-27609 (28). 
There are several possible explanations for these seemingly 
discrepant results.
First, the timing of LPS and influenza challenges may be 
crucial; in the abovementioned studies, a time interval of 24 h 
or less between LPS and influenza/viral ligands was employed, 
whereas we employed an interval of 7  days to ensure that the 
acute LPS-induced immune response had subsided but endo-
toxin tolerance was profound. This explanation is supported by 
two murine studies that showed protection against influenza 
infection in terms of mortality when LPS was administered 12 
and 24 h as well as 3 days before influenza infection, but not when 
an interval of 7 days was employed (31, 32). These findings in 
mice strongly suggest that there were no major alterations in the 
immune response using this interval.
A second possible explanation for the absence of a reduced 
immune response toward Fluenz after LPS administration 
is represented by compartment-specific effects. Although 
in vivo endotoxin tolerance is likely due to reprogramming of 
tissue-resident macrophages, which are assumed to be the main 
cytokine producers in response to LPS administration in  vivo 
(4), it is unknown which tissues are actually affected and to what 
extent. It can be speculated that the mucosal compartment, in 
which Fluenz is administered and the initial antiviral immune 
response mounted, is not tolerized by a preceding LPS adminis-
tration. To the best of our knowledge, there are no other studies 
that investigated the effects of a systemic bacterial challenge on 
a subsequent mucosal challenge. Nevertheless, there are data 
that show compartment-specific effects concerning endotoxin 
tolerance. For instance, a study in which murine peritoneal and 
alveolar macrophages were ex vivo restimulated with LPS after a 
systemic LPS challenge showed a marked discrepancy between 
these two cell types from different compartments: alveolar 
macrophages were not displaying endotoxin tolerance, while 
peritoneal macrophages did (33). The attenuated susceptibility 
of pulmonary macrophages to develop endotoxin tolerance is 
supported by other work in mice that were intrapulmonary chal-
lenged with 1 µg LPS for four consecutive days, followed by a 
pulmonary LPS challenge with 10 µg 24 h later. Although TNF-α 
levels were attenuated in chronic LPS-exposed mice upon the 
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final LPS challenge compared with PBS-pretreated mice, IL-6 
levels were increased, accompanied by unrestricted neutrophil 
recruitment to the alveolar space (34). It was speculated that this 
represents a mechanism by which the lungs protect themselves 
against pulmonary bacterial infections (34). In addition, chronic 
pulmonary LPS exposure did not confer cross-tolerance to the 
TLR2 ligand Pam3Cys (34). Taken together, similar to the lung, 
the nasal mucosa might be less sensitive to tolerance. This com-
partmentalization could also explain why primary virus infec-
tions entering the body through the nasal mucosa have not been 
reported following sepsis-induced immunosuppression, while 
latent viruses that are already present in the systemic compart-
ment may induce infection in the immunocompromised host 
through reactivation.
Third, one may argue that the absence of an effect of preceding 
LPS administration on antiviral responses in our study might be 
that the human endotoxemia model and the resulting immu-
nosuppressive effect is too mild to affect antiviral immunity. 
However, the profound (>70%) suppression of the response to 
a subsequent LPS challenge, also 1 week after the first LPS chal-
lenge, indicates that this model is able to induce clinically relevant 
tolerance in case of rechallenge with LPS.
Finally, the pathophysiology induced by the use of the LAIV 
Fluenz may not be comparable with the actual pathogenic 
influenza virus, because it is an attenuated virus that may not 
show same infectivity, tissue tropism and virus dissemination as 
actual influenza. Furthermore, the immune evasion strategies/
other specific immune parameters of live virus in the host cells 
might not be shown by the LAIV, as discussed elsewhere (35, 36). 
Nevertheless, aforementioned work in mice using a pathogenic 
influenza strain (31, 32) corroborates our findings that an interval 
of 7 days does not result in an altered response upon challenge 
with influenza. As alluded before, we believe that using LAIVs 
such as Fluenz is the most accurate way to model an actual 
influenza infection in humans in vivo in a safe manner. Use of 
a primate model (37–39) could definitively exclude that the lack 
of effects by LPS pretreatment is not due to differences between 
LAIVs and pathogenic influenza virus.
The lack of an in vivo interaction found in this study might 
explain why no adverse effects of the live-attenuated influenza 
vaccine have been reported in immunocompromised patients, 
including the elderly and young children (40–43), while 
immunogenicity of the vaccine is unaltered (40, 43). This 
is demonstrated by the absence of an exaggerated immune 
response or excessive viral replication, and seroconversion 
rates similar to those observed in healthy young adults. 
Nevertheless, the vaccine is not recommended for immuno-
compromised patients (29).
The Fluenz-induced immunological effects observed in 
this study are in accordance with previous work (29, 44–48). 
The proportion of subjects that displayed detectable influenza 
virus in nasal washings after Fluenz vaccination (47), as well 
as the increased production of cytokines in nasal wash (45) 
is in line with previous findings. Moreover, Fluenz-induced 
robust serum antibody responses (46), especially for the H3N2 
strain (29). The overall high seroconversion rate in our study 
could be explained by our study population, which are young, 
healthy males with competent immune systems, efficient in 
eliminating Fluenz.
A limitation to our study is the fact that we performed the 
study during the winter season could have influenced the results. 
Although we tested for the presence of various influenza strains, 
other respiratory viruses are prevalent in the winter period as 
well, such as the human rhinovirus and respiratory syncytial 
virus, and it has been demonstrated that viral co-infections may 
alter the disease course (49–51). Also, the reactivation of latent 
viruses, such as herpes simplex virus, CMV, and Epstein–Barr 
virus are common in this season, which could have affected the 
immune response as well (52, 53).
In conclusion, challenge with the bacterial ligand LPS does 
not affect the mediated response toward a subsequent viral 
challenge consisting of the live-attenuated influenza vaccine 
Fluenz. Our results suggest that immune suppression after 
bacterial infection does not alter the response to a subsequent 
viral infection.
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